← Back to Home

Formosa Pharmaceuticals Submits European Clinical Trial Application for TSY-110, Advancing a HER2 Breast Cancer ADC Biosimilar

Linking an antibody to a cytotoxic drug adds another layer of complexity to biosimilar development. TSY-110 is intended for direct comparison with Kadcyla, but submitting the application is only one step; human evidence and future pricing remain unknown.

By SURL BioNews

More biosimilar options for targeted breast cancer treatment could bring competition to treatment costs, provided that the candidates establish sufficient evidence of similarity. Formosa Pharmaceuticals announced on August 28, 2026, that it had submitted a clinical trial application for TSY-110 to European regulatory authorities, with plans for a pivotal comparative trial against Roche’s antibody-drug conjugate (ADC) Kadcyla.

TSY-110, also known as EG12043, is being jointly developed by Formosa Pharmaceuticals and Mycenax Biotech, with Kadcyla (ado-trastuzumab emtansine) as the reference product. Kadcyla is used in specific settings involving HER2-positive early and metastatic breast cancer. This application is intended to establish clinical comparative evidence for the biosimilar candidate and does not mean that TSY-110 has received authorization for the trial or marketing approval.

This type of drug links the HER2-recognizing antibody trastuzumab to the cytotoxic drug DM1, using the antibody to deliver the drug to cancer cells with higher HER2 expression. Developing a biosimilar requires addressing not only the antibody itself but also the drug payload, linker structure, and characteristics of the finished conjugated product. The amount of drug carried by each antibody is also an important part of the comparison.

According to the company’s announcement and a summary by the Institute for Biotechnology and Medicine Industry, the planned trial will directly compare the safety, tolerability, pharmacokinetics, and immunogenicity of TSY-110 and Kadcyla—the latter two referring to how the drug behaves in the body and whether it triggers an immune response. The company said the trial protocol was designed in accordance with U.S. and European regulatory scientific guidelines, but these public materials did not provide enrollment numbers, the full statistical design, or a timeline for results.

The supporting evidence currently remains largely based on company disclosures. Formosa Pharmaceuticals said structural analyses and preclinical assessments showed that TSY-110 has high analytical similarity, a consistent drug-to-antibody ratio, and plasma pharmacokinetics similar to those of the reference product. However, the announcement did not provide complete data or the scope of the comparisons, so it cannot yet establish that the two products have been proven comparable in efficacy or risk in patients.

BioSpectrum Asia separately reported that the company completed a Type 2 meeting under the U.S. FDA’s Biosimilar Product Development Program in 2026, reaching broad agreement on the direction of clinical trial design and chemistry, manufacturing, and controls strategies. The report also noted that the development and manufacturing network combines Mycenax’s antibody capabilities with Formosa Laboratories’ ADC bioconjugation platform. Regulatory discussions and manufacturing process integration help advance development, but subsequent data review is still required.

For patients, the significance of this program lies in its potential to expand future treatment options and create room for competition on costs. However, lower costs remain a development goal, with no launch price or actual savings figures available yet. The next questions are whether the trial will be authorized to begin and whether the comparative results can support an application for TSY-110 as a biosimilar to Kadcyla.

References

  1. PR Newswire
  2. Formosa Pharmaceuticals
  3. BioSpectrum Asia
  4. Institute for Biotechnology and Medicine Industry (IBMI)